Diabetes

Illustration of the concept of layoff and downsizing of staff

Biomea cuts staff, drops leukemia asset in metabolic shift

Biomea is homing in on lead asset icovamenib, a menin inhibitor designed to address the underlying cause of diabetes, and a preclinical GLP-1 agonist.

Darren Incorvaia May 5, 2025 6:59pm

Insulet taps former J&J medtech head Ashley McEvoy to be CEO

Apr 28, 2025 11:00am

Ypsomed sells diabetes business to focus on GLP-1 self-injectors

Apr 23, 2025 6:20am

Medtronic Simplera Sync MiniMed 780G meal

Medtronic nets FDA approval for Simplera Sync glucose tracker

Apr 21, 2025 11:00am

Dexcom wins FDA clearance for 15-day G7 CGM sensor

Apr 10, 2025 11:31am

BiomX's bacteria-killing virus reduces bone ulcers in phase 2

Mar 31, 2025 9:05am